Publisher
Springer Science and Business Media LLC
Reference92 articles.
1. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S (2010) Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monitor: Int Med J Experimental Clin Res 16(2):BR61–67
2. Ahn JH, Kim M, Park S, Jang W, Park J, Oh E, Cho JW, Kim JS, Youn J (2020) Prolonged-release melatonin in Parkinson’s disease patients with a poor sleep quality: a randomized trial. Parkinsonism Relat Disord 75:50–54
3. Al-Buhadily AK, Al-Uqabi RU, Al-Gareeb AI (2023) Evaluation of Protective Effect of Metformin in rats with experimental osteoarthritis. Mustansiriya Med J 22(1):50–53
4. Al-Kuraishi AH, Khalil HI, Hasan HH, Al-Kuraishy HM (2021) Are alterations in melatonin and inflammatory cytokine serum levels linked with recurrent abortion in pregnant women with acute toxoplasmosis: the interacted nexus. Parity 1:0–94
5. Al-Kuraishi AH, Khalil HI, Hassan HH, Al-kuraishy HM (2023) Placental dysfunction and acute toxoplasmosis: the role of melatonin in relation to inflammatory cytokines Interleukin-10 and Interleukin-12. J Microscopy Ultrastructure 11(2):87–91